Epiomic Epidemiology Series: Hidradenitis Suppurativa Forecast in 21 Major Markets 2018–2028

June 2018 | 88 pages | ID: E4FB54EED4FEN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Forecast Report on Hidradenitis Suppurativa in 21 Major Markets

Hidradenitis suppurativa (HS) is a chronic multifactorial inflammatory skin disease with a serious negative effect on patient quality of life. It presents with painful lesions—nodules, abscesses, sinus tracts, etc.—affecting mainly axillae, perineal and perianal areas and buttocks, as well as infra- and intermammary areas. The alternative name of the disease is acne inversa, and it usually affects areas unaffected by acne vulgaris.

This report provides the current prevalent population for HS across 21 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Denmark, Russia, Turkey, Japan, China, South Korea, Singapore, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, HS patients grouped by disease stages, grades, phenotypes, number and type of lesions, certain parameters, as well as signs and comorbidities have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of HS include:

• Infections
• Lymphatic obstruction
• Contractures with reduced mobility
• Perianal and perirectal sinuses and fistulae
• Pyoderma gangrenosum
• Ulcerative colitis
• Crohn's disease
• Arthropathy
• Overweight/obesity
• Depression
• Squamous cell carcinoma

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

REASON TO BUY

• Ability to quantify patient populations in global HS market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of HS and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding of the impact of specific co-morbid conditions on the prevalent population of HS patients.
• Identification of HS patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of HS patients.

Contents

INTRODUCTION
CAUSE OF THE DISEASE
RISK FACTORS & PREVENTION
DIAGNOSIS OF THE DISEASE
VARIATION BY GEOGRAPHY/ETHNICITY
DISEASE PROGNOSIS & CLINICAL COURSE
KEY COMORBID CONDITIONS/FEATURES ASSOCIATED WITH THE DISEASE
METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
TOP-LINE PREVALENCE FOR HIDRADENITIS SUPPURATIVA
FEATURES OF HIDRADENITIS SUPPURATIVA PATIENTS
AREAS AFFECTED BY HIDRADENITIS SUPPURATIVA
COMORBIDITIES OF HIDRADENITIS SUPPURATIVA PATIENTS
ABBREVIATIONS USED IN THE REPORT
OTHER BLACK SWAN SERVICES & SOLUTIONS
REPORTS & PUBLICATIONS
ONLINE EPIDEMIOLOGY DATABASES
ONLINE PHARMACEUTICAL PRICING DATABASE
REFERENCES
APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Questions to help diagnosis of HS
Table 2. Hurley’s stages for the classification of HS
Table 3. Prevalence of hidradenitis suppurativa, total (000s)
Table 4. Prevalence of hidradenitis suppurativa, males (000s)
Table 5. Prevalence of hidradenitis suppurativa, females (000s)
Table 6. Patients with hidradenitis suppurativa by Hurley stage, total (000s)
Table 7. Patients with hidradenitis suppurativa by Sartorius score, total (000s)
Table 8. Patients with hidradenitis suppurativa by latent class phenotype, total (000s)
Table 9. Patients with hidradenitis suppurativa by symptom group, total (000s)
Table 10. Patients with hidradenitis suppurativa by number of lesions, total (000s)
Table 11. Patients with hidradenitis suppurativa by BMI, total (000s)
Table 12. Patients with hidradenitis suppurativa by smoking status, total (000s)
Table 13. Hidradenitis suppurativa patients with a family history of the disease, total (000s)
Table 14. Hidradenitis suppurativa patients with affected abdomen, total (000s)
Table 15. Hidradenitis suppurativa patients with affected chest/breast/inframammary, total (000s)
Table 16. Hidradenitis suppurativa patients with affected axilla, total (000s)
Table 17. Hidradenitis suppurativa patients with affected perineal or perianal area, total (000s)
Table 18. Hidradenitis suppurativa patients with affected scrotum, males (000s)
Table 19. Hidradenitis suppurativa patients with affected groin or thigh, total (000s)
Table 20. Hidradenitis suppurativa patients with affected buttock or gluteal cleft, total (000s)
Table 21. Hidradenitis suppurativa patients with affected neck or ear, total (000s)
Table 22. Hidradenitis suppurativa patients with diabetes mellitus, total (000s)
Table 23. Hidradenitis suppurativa patients with arterial hypertension, total (000s)
Table 24. Hidradenitis suppurativa patients with metabolic syndrome, total (000s)
Table 25. Hidradenitis suppurativa patients with depression, total (000s)
Table 26. Hidradenitis suppurativa patients with pilonidal cyst, total (000s)
Table 27. Hidradenitis suppurativa patients with folliculitis, total (000s)
Table 28. Hidradenitis suppurativa patients with current acne, total (000s)
Table 29. Abbreviations and acronyms used in the report
Table 30. USA prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 31. USA prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 32. Canada prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 33. Canada prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 34. France prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 35. France prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 36. Germany prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 37. Germany prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 38. Italy prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 39. Italy prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 40. Spain prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 41. Spain prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 42. UK prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 43. UK prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 44. Poland prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 45. Poland prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 46. Netherlands prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 47. Netherlands prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 48. Belgium prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 49. Belgium prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 50. Denmark prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 51. Denmark prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 52. Russia prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 53. Russia prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 54. Turkey prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 55. Turkey prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 56. Japan prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 57. Japan prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 58. China prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 59. China prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 60. South Korea prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 61. South Korea prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 62. Singapore prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 63. Singapore prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 64. Australia prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 65. Australia prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 66. Brazil prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 67. Brazil prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 68. Mexico prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 69. Mexico prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Table 70. Argentina prevalence of hidradenitis suppurativa by 5-yr age cohort, males (000s)
Table 71. Argentina prevalence of hidradenitis suppurativa by 5-yr age cohort, females (000s)
Figure 1. Hidradenitis Suppurativa Score scorecard